Adoptive cell therapy (ACT) is a kind of immunotherapy, in which T cells are genetically modified to express a chimeric antigen receptor or T cell receptor.
On July 11, 2022, the United States District Court for the District of Kansas approved a $264 million settlement against Mylan and certain of its subsidiaries in the case In Re EpiPen (Epinephrine Injection, USP) Marketing, .
On July 11, 2022, the United States District Court for the District of Kansas approved a $264 million settlement against Mylan and certain of its subsidiaries in the case In Re EpiPen.